You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Preoperative Diagnosis of Lynch Syndrome With DNA Mismatch Repair Immunohistochemistry on a Diagnostic Biopsy

Warrier, S. K. M.B.B.S., F.R.A.C.S.1,4; Trainer, A. H. F.R.A.C.P., Ph.D.2; Lynch, A. C. M.B.Ch.B., M.Med.Sci., F.R.A.C.S., F.C.S.S.A.N.Z.1; Mitchell, C. M.B.B.S., F.R.C.P.A.3; Hiscock, R. M.B.B.S., F.A.N.Z.C.A., Grad.Dip.Stat.4; Sawyer, S. B.Sc.2; Boussioutas, A. M.B.B.S., F.R.A.C.P.2,5; Heriot, A. G. M.D., M.B.A., F.R.A.C.S.1

Diseases of the Colon & Rectum:
doi: 10.1097/DCR.0b013e318231db1f
Original Contribution
Abstract

BACKGROUND: DNA mismatch repair immunohistochemistry on tumor tissue is a simple, readily available, and cost-effective method of identifying patients with Lynch syndrome in the postoperative setting. The aim of the study was to assess whether the mismatch repair status of a colorectal cancer can be confirmed by mismatch repair immunohistochemistry on preoperative biopsy.

DESIGN: Germline positive patients with Lynch syndrome were identified from a prospectively collected Familial Cancer Clinic database. Preoperative colorectal cancer biopsy specimens were obtained from the source pathology provider to generate a cohort of matched preoperative and postoperative specimens. The specimens were sectioned and stained for 4 mismatch repair proteins (MLH1, MSH2, MSH6, PMS2). An age-matched cohort to compare specimens was selected from Bethesda positive but mismatch repair immunohistochemistry negative patients. All slides were reviewed by a single blinded pathologist. The Wilson method was used to calculate a true underlying proportion of patients for whom the preoperative result matched the postoperative test result with a 95% confidence interval.

RESULTS: Of 128 germline positive mutation carriers, 40 patients (mean age 41, SD 11.3) had colorectal resections. Thirty-three preoperative specimens were retrievable and were matched with biopsies from 33 controls. The germline mutations included in the study were 8 MLH1, 19 MSH2, 3 MSH6, and 2 PMS2. In patients where germline positive status was known, sensitivity was 100% (95% CI 89.2–100) and specificity was 100% (95% CI 89.2–100). Identical sensitivity and specificity were observed in 33 age-matched patients. The sensitivity of the endoscopic biopsy in predicting germline status was 94.9% (95% CI 80.4–98.3).

CONCLUSION: The mismatch repair disease status of a colorectal cancer can be reliably confirmed by mismatch repair immunohistochemistry on a diagnostic colorectal cancer biopsy sample before definitive surgery. Ascertaining a diagnosis of Lynch syndrome before definitive surgery can influence surgical planning.

Author Information

1 Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

2 Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

3 Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

4 Epworth HealthCare, Melbourne, Victoria, Australia

5 Department of Medicine (RMH/WH), University of Melbourne, Footscray, Victoria, Australia

Financial Disclosures: None reported.

Presented at the meeting of The American Society for Colon and Rectal Surgeons, Vancouver, BC, Canada, May 14 to 18, 2011.

Correspondence: Alexander Heriot, M.D., M.B.A., F.R.A.C.S., Department of Surgical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Melbourne, VIC 8006, Australia. E-mail: Alexander.Heriot@petermac.org

© The ASCRS 2011